September 5, 2025mAbsOpen Access

A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

HGHollie B. S. Griffiths NJN. D. Jones MVMattia Vitale

Discussion

Member takes

Implication

Observational analysis shows BVX001 improves tumor selectivity and reduces leukemic stem cells in acute myeloid leukemia, suggesting its potential as a targeted therapy.

Key Points

BVX001 induced significant tumor regression and improved overall survival in AML models.
CD33 and CD7 co-expression occurs in about one-third of AML patients, linking it to an aggressive subtype.
The bispecific antibody-drug conjugate spares healthy myeloid progenitors while targeting malignant cells.
Targeting CD33 and CD7 simultaneously provides optimal delivery of the drug's cytotoxic payload, enhancing efficacy.

Cite This Study

Griffiths et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477ccce https://doi.org/10.1080/19420862.2025.2551205

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis shows BVX001 improves tumor selectivity and reduces leukemic stem cells in acute myeloid leukemia, suggesting its potential as a targeted therapy.

A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider